For US healthcare professionals only.

ELOCTATE® has a demonstrated safety profile1

In clinical trials, zero inhibitors were detected in previously treated patients1

  • Formation of neutralizing antibodies (inhibitors) to factor VIII has been reported following administration of ELOCTATE, including in previously untreated patients
  • Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests

The most frequently occurring adverse reactions (0.5%–<1% of patients) in clinical trials were arthralgia, malaise, myalgia, headache, and rash1

  • Two subjects with cardiovascular risk factors each experienced a serious adverse reaction of myocardial infarction during the study
Calculate an ELOCTATE dose for different clinical needs button-shadow